Risk assessment for vaccination programmes in a pandemic. A Swedish model for efficacy and safety during COVID-19
Downloads
Download data is not yet available.
References
1. Zethelius B, Rubin J, Pihlström N, Liminga UW, Back H, Aronsson B, et al. Overview of approved COVID-19 vacines in the EU, recommendations for use in Sweden and vaccine uptake over time. Report from the Swedish Medical Products Agency and the Public Health Acency of Sweden. Ups J Med Sci. 2025;130:e12937. doi: https://doi.org/10.48101/ujms.v130.12937
2. Buonocore SM, van der Most RG. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front Immunol. 2022;13:902840. doi: https://doi.org/10.3389/fimmu.2022.902840
3. Ljung R, Sundstrom A, Grunewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci. 2021;126:8136. doi: https://doi.org/10.48101/ujms.v126.8136
2. Buonocore SM, van der Most RG. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front Immunol. 2022;13:902840. doi: https://doi.org/10.3389/fimmu.2022.902840
3. Ljung R, Sundstrom A, Grunewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci. 2021;126:8136. doi: https://doi.org/10.48101/ujms.v126.8136
Published
2025-11-24
How to Cite
Wikström , G., & Welsh , M. (2025). Risk assessment for vaccination programmes in a pandemic. A Swedish model for efficacy and safety during COVID-19. Upsala Journal of Medical Sciences, 130, e13602. https://doi.org/10.48101/ujms.v130.13602
Section
Editorial
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
